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Purpose: To prospectively compare clinical breast examination
(CBE), mammography, ultrasonography (US), and con-
trast material–enhanced magnetic resonance (MR) imag-
ing for screening women at genetic-familial high risk for
breast cancer and report interim results, with pathologic
findings as standard.
Materials and
Methods:
Institutional review board of each center approved the
research; informed written consent was obtained. CBE,
mammography, US, and MR imaging were performed for
yearly screening of BRCA1 or BRCA2 mutation carriers,
first-degree relatives of BRCA1 or BRCA2 mutation carri-
ers, or women enrolled because of a strong family history
of breast or ovarian cancer (three or more events in first-
or second-degree relatives in either maternal or pater-
nal line; these included breast cancer in women younger
than 60 years, ovarian cancer at any age, and male
breast cancer at any age).
Results: Two hundred seventy-eight women (mean age, 46 years 
12 [standard deviation]) were enrolled. Breast cancer was
found in 11 of 278 women at first round and seven of 99 at
second round (14 invasive, four intraductal; eight were
10 mm in diameter). Detection rate per year was 4.8%
(18 of 377) overall; 4.3% (11 of 258) in BRCA1 or BRCA2
mutation carriers and first-degree relatives of BRCA1 or
BRCA2 mutation carriers versus 5.9% (seven of 119) in
women enrolled because of strong family history; and
5.3% (nine of 169) in women with previous personal
breast and/or ovarian cancer versus 4.3% (nine of 208) in
those without. In six (33%) of 18 patients, cancer was
detected only with MR imaging. Sensitivity was as follows:
CBE, 50% (95% confidence interval [CI]: 29%, 71%);
mammography, 59% (95% CI: 36%, 78%); US, 65% (95%
CI: 41%, 83%); and MR imaging, 94% (95% CI: 82%,
99%). Positive predictive value was as follows: CBE, 82%
(95% CI: 52%, 95%); mammography, 77% (95% CI: 50%,
92%); US, 65% (95% CI: 41%, 83%); and MR imaging,
63% (95% CI: 43%, 79%).
Conclusion: Addition of MR imaging to the screening regimen for high-
risk women may enable detection of otherwise unsus-
pected breast cancers.
 RSNA, 2007
1 From the University of Milan School of Medicine, De-
partment of Medical and Surgical Sciences, Unit of Radi-
ology, IRCCS Policlinico San Donato, Via Morandi 30,
20097 San Donato Milanese, Milan, Italy (F.S.); and De-
partment of Cell Biology and Neurosciences, Istituto Su-
periore di Sanita`, Rome, Italy (F.P.). The remaining au-
thors and their affiliations are listed at the end of this
article. From the 2004 RSNA Annual Meeting. Received
December 5, 2005; revision requested January 25, 2006;
revision received February 28; accepted April 3; final ver-
sion accepted June 30. The HIBCRIT study was supported
by the Italian Ministry of Health (Ricerca Finalizzata 1%
98/JT/T) and Istituto Superiore di Sanita` (ricerca corrente
C3A3/2004) and coordinated by the Istituto Superiore di
Sanita`, Rome, Italy. Address correspondence to F.S.
(e-mail: f.sardanelli@grupposandonato.it ).
 RSNA, 2007
OR
IG
IN
AL
RE
SE
AR
CH

BR
EA
ST
IM
AG
IN
G
698 Radiology: Volume 242: Number 3—March 2007
Note: This copy is for your personal non-commercial use only. To order presentation-ready 
copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights.
The cumulative lifetime risk ofbreast cancer is greatly differentfor women with a hereditary pre-
disposition for this disease from that for
women in the general population. Al-
though breast cancer affects a range of
as many as one in seven to one in 11
women inWestern countries (1,2), spo-
radic disease accounts for about 85%–
95% of the occurrences. The remaining
5%–15% of breast cancers are clus-
tered in families with high breast cancer
incidence (3–5). For women in the lat-
ter group, an inherited predisposition
may result in an early onset of the dis-
ease (typically in the premenopausal pe-
riod) and in a lifetime risk greater than
50%–60% (3–7).
About 50% of the occurrences in
high-risk families can be explained by
the dominant autosomal inheritance of
the deleterious BRCA1 or BRCA2muta-
tions on the 17q21 or the 13q12 chro-
mosomal location, respectively, with in-
complete penetrance (6,8,9). BRCA1
mutations are associated with an in-
creased risk of ovarian cancer, whereas
BRCA2 mutations may be associated
with male breast cancer. Breast cancers
in very young women (younger than 35
years) are frequently associated with
BRCA1 mutations (10). Moreover,
breast cancers in BRCA1 mutation car-
riers are more frequently high grade
and estrogen receptor negative com-
pared with sporadic cancers (11,12),
and they are associated with less favor-
able survival (13,14).
The strategy for surveillance of
high-risk women is different from that
for surveillance of the general popula-
tion (eg, annual mammography for
women older than 40 years in the
United States and biannual mammogra-
phy for women older than 50 years in
many European countries). Screening
for high-risk women should begin at a
younger age and with no more than a
1-year interval between examinations.
As reported in a recent review (15),
researchers determined that contrast
material–enhanced magnetic resonance
(MR) imaging is highly sensitive for
identification of breast cancer in a large
spectrum of clinical situations. Because
of lower values for specificity and posi-
tive predictive value (PPV), with con-
trast-enhanced MR imaging, however,
unnecessary breast biopsy has been re-
ported because of false-positive findings
(16,17), especially in premenopausal
women (18,19) and also in high-risk
women (20).
Findings from two retrospective
(21,22) and five prospective studies
(23–27) indicated that contrast-enhanced
MR imaging is useful in the screening of
high-risk women. These single- and
multicenter studies differed in the num-
ber of diagnostic modalities used for
comparative evaluation, in enrollment
criteria, in selected age groups, and in
levels of cumulative lifetime risk of
breast cancer. The purpose of our mul-
ticenter trial was to prospectively com-
pare the sensitivity of clinical breast ex-
amination (CBE), mammography, ultra-
sonography (US), and contrast-enhanced
MR imaging for the screening of women
at genetic-familial high risk for breast
cancer and to report our interim re-
sults, with pathologic findings as the ref-
erence standard.
Materials and Methods
Study Design and Population
An open prospective nonrandomized
multicenter comparative trial was de-
signed (7), and the institutional review
board of each center approved the re-
search. Informed written consent was
obtained from each subject enrolled in
the study. We planned to enroll asymp-
tomatic subjects at high risk for breast
cancer, women at least 25 years of age
and men at least 50 years of age, who
were (a) carriers of BRCA1 or BRCA2
mutations, as demonstrated with ge-
netic testing, or subjects with personal
unknown mutational status but who
were first-degree relatives of BRCA1 or
BRCA2 mutation carriers or (b) sub-
jects with a strong family history of
breast or ovarian cancer who had three
or more events of breast or ovarian can-
cer in first- or second-degree relatives
in either the maternal or the paternal
line. These three or more events could
have included female breast cancer in
relatives younger than 60 years, ovarian
cancer in relatives at any age, or male
breast cancer in relatives at any age.
The occurrence of previous breast
cancer and/or ovarian cancer in the
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BI-RADS  Breast Imaging Reporting and Data System
CBE  clinical breast examination
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Advances in Knowledge
 By using a multimodality surveil-
lance approach that included con-
trast-enhanced MR imaging, the
detection rate of breast cancer in
asymptomatic high-risk women
was 4.8% in our study.
 In women enrolled only on the
basis of well-defined criteria for
strong family history of breast
and/or ovarian cancer, the detec-
tion rate was not significantly dif-
ferent from that of those enrolled
for positive BRCA1 or BRCA2 ge-
netic testing (or for being first-
degree relatives of subjects with
positive BRCA1 or BRCA2 genetic
testing).
 Contrast-enhanced MR imaging
showed a high sensitivity (94%;
33% of patients with cancer de-
tected only with contrast-en-
hanced MR imaging), with an ac-
ceptable positive predictive value
(63%) that was close to that of US
(65%); the addition of contrast-
enhanced MR imaging to the
screening regimen of high-risk
women may enable the detection
of otherwise unsuspected breast
cancers.
 Contrast-enhanced MR imaging
showed a high sensitivity in the
detection of multiple malignant
foci in the same breast in high-
risk women with invasive cancers.
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subject to be enrolled could contribute
to the number of events needed to meet
the second criterion defined previously.
A multifocal unilateral cancer was re-
garded as one event. A multicentric uni-
lateral cancer was regarded as two
events. An ipsilateral metachronous
breast cancer was regarded as a new
event if it was located at least at 5 cm
from the previous cancer. Bilateral syn-
chronous breast cancers were regarded
as two different events.
Subjects with a history of personal
breast cancer were included (28), pro-
vided that at least one breast was not
completely excised. Exclusion criteria
were pregnancy, breast-feeding, cur-
rent chemotherapy, terminal illness,
and contraindications to MR imaging.
History of surveillance imaging prior to
entry into the study was not specifically
recorded. For each enrolled patient, we
planned two annual rounds of assess-
ment with CBE, mammography, US,
and contrast-enhanced MR imaging and
at least a 1-year follow-up with CBE,
mammography, and US. At each screen-
ing event, each of these tests was per-
formed by an independent physician
who was unaware of the results ob-
tained by the other three colleagues.
Centers were asked to plan the in-
dependent examinations for each screen-
ing event in the same day for as many
enrolled subjects as possible. When we
considered the need for planning con-
trast-enhanced MR imaging during the
2nd week of the menstrual cycle in pre-
menopausal women and logistic prob-
lems (eg, different locations for mam-
mography, US, and MR imaging facili-
ties; members of the same family
preferred to have the examination on
the same day), a maximum time of 1
month for performance of the four diag-
nostic modalities was allowed. In some
instances, justified by particular condi-
tions, the central unit accepted a maxi-
mum delay of 2 months.
A national health institution (Istituto
Superiore di Sanita`, Rome, Italy) was
responsible for multicenter project de-
sign, central coordination, and data
management and funding (central unit).
This institution was not directly in-
volved in the enrollment or in the per-
formance of genetic testing, CBE, mam-
mography, breast US, and contrast-en-
hanced MR imaging. Seventeen centers
in 14 Italian towns participated. The
first center was activated in June 2000,
and the 17th center was activated in
November 2003; four institutes for can-
cer research and treatment, 12 univer-
sity hospitals, and one general hospital
were included. Quality assessment pro-
grams were regularly performed in the
radiology departments of these institu-
tions. At each center, examinations
were performed, and findings from the
examinations were interpreted with the
supervision of a radiologist who had at
least 10 years of experience in breast
imaging; moreover, other physicians
were involved in the trial at each cen-
ter, and the centers and names of
those involved appear at the end of
this article.
During the first phase of the study
(from June 2000 to December 2002),
the enrollment was limited to the first
criterion described before; preliminary
results for this phase, which pertained
to the first eight patients in whom
breast cancer was detected, were re-
ported during an international work-
shop in early 2002 (7). In January 2003,
enrollment on the basis of the second
criterion was also opened. The general
plan of the trial was aimed at enrolling
approximately 500 subjects in about 6
years, with about 50% fulfilling the first
criterion and about 50% fulfilling the
second criterion. For each of the three
diagnostic imaging modalities (mam-
mography, US, and contrast-enhanced
MR imaging), performed in nonran-
domized order, the results of local pro-
spective independent readings are in-
cluded in the data presented here. Each
reader was aware of the high-risk condi-
tion of the women but was blinded to
the results of the other three diagnostic
modalities. During the second round,
the readers were aware of the results
from the first annual round.
Genetic Testing
Genetic testing for identification of dele-
terious BRCA1 and BRCA2 mutations
included the use of individual or com-
bined procedures, such as direct se-
quencing (29–31), protein truncation
testing (29), single-strand conformation
polymorphism (32), or mutation screen-
ing with denaturing chromatography (33).
Clinical Breast Examination
Thirty-nine physicians performed CBE
in the 17 centers. Findings of each ex-
amination were coded as normal, sug-
gestive of benign disease, indetermi-
nate, suspicious for malignant disease,
or highly suggestive of malignant dis-
ease. Palpable nodules that were judged
as benign or indeterminate but were
clearly benign at mammography and/or
US (eg, cysts, calcified fibroadenomas)
were not considered in the current re-
port. In the present analysis, for each
patient who had cancer during the trial,
the cancer was considered palpable if at
least one of the pathologically demon-
strated malignant foci was coded at CBE
as indeterminate, suspicious for malig-
nant disease, or highly suggestive of ma-
lignant disease. Clinical findings were
marked on a diagram and correlated
with imaging findings after reporting.
Mammographic Examination
Bilateral two-view mammography (uni-
lateral in women who previously had
undergone one-breast mastectomy) was
performed with screen-film units with a
rotating anode, a 0.3–0.1-mm focus, a
focus-film distance of 55 cm or greater,
homogeneous breast compression, a
mobile grid, and automatic exposure
control. Dedicated daylight processing
was performed. Standard mediolateral
oblique and craniocaudal projections
were acquired. Further dedicated mam-
mograms (ie, magnification, spot com-
pression, or other additional views)
were obtained when necessary.
When an enrolled subject under-
went a previous mammographic exami-
nation performed within the 2 months
preceding enrollment, the mammogram
from that examination was acquired as
part of the study after a quality check; if
mammography was performed more
than 2 months before the enrollment,
the first round of complete multimodal-
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ity assessment was planned 12 months
after the previous mammogram was ob-
tained.
Images from mammographic exami-
nations were evaluated by one reader.
Evaluations were performed by radiolo-
gists with at least 10 years of experience
in breast imaging, and findings were
classified by using the five-point scale of
the Breast Imaging Reporting and Data
System (BI-RADS) (34). Thirty-nine ra-
diologists interpreted the mammograms
in the 17 centers. The density pattern
was classified according to two catego-
ries: breasts with more than 50% of the
breast occupied by fibroglandular den-
sity as a mean of the two mammo-
graphic views and breasts with 50% or
less of the breast occupied by fibroglan-
dular density as a mean of the two mam-
mographic views.
US Examination
US examinations were performed by ra-
diologists with at least 10 years of expe-
rience in breast imaging. Both breasts
were systematically examined by using
vertical, horizontal, radial, and antira-
dial scans obtained by a radiologist who
reported the findings of the examination
by using the five-point BI-RADS scale
(35). Forty-one physicians performed
and interpreted the US breast examina-
tions in the 17 centers. Transducers
with a frequency of 10 MHz or greater
were used in 14 centers, transducers
with a frequency of 7.5 MHz or greater
were used in two centers, and only a
transducer with a frequency of 7.5 MHz
was used in one center; transverse res-
olution of 0.5 mm or less and lateral-
transverse resolution of 1 mm or less
were used.
Contrast-enhanced MR Imaging
Contrast-enhanced MR imaging was
performed at 1.5 T (12 centers) or 1.0 T
(four centers), whereas at one center
both field strengths were used because
of the change of equipment during the
trial. The MR units, equipped with ac-
tively shielded gradients of 15 mT/m or
greater, were purchased from three
manufacturers (GE Medical Systems,
Milwaukee, Wis; Philips Medical Sys-
tems, Best, the Netherlands; or Sie-
mens Medical Solutions, Erlangen, Ger-
many). Dedicated synchronous breast
coils were used for bilateral studies (or
unilateral studies when a mastectomy
previously had been performed) with
the patient in the prone position. The
examination was planned on the 7th–
14th day of the menstrual cycle in pre-
menopausal women but without sched-
uling limitations in postmenopausal
women.
A long venous catheter access was
obtained by using a plastic cannula in a
cubital vein. After localizing scout views
were obtained, a contrast-enhanced dy-
namic three-dimensional T1-weighted
spoiled gradient-echo sequence was
performed in the transverse or coronal
plane. The parameters were as follows:
repetition time, 13 msec or less; flip
angle, 20°–30°; partition thickness, 3
mm or smaller; intersection gap, none;
number of partitions, 40–128 (to cover
both breasts entirely); and acquisition
time, not longer than 120 seconds. The
echo time was chosen to prevent fat-
water signal opposition at 1.0 or 1.5 T
(36). The field of view and image matrix
were combined to obtain a pixel size of
1.4  1.4 mm or less.
An unenhanced sequence was per-
formed before contrast agent injection.
Then, 0.1 mmol/kg of one of the com-
mercially available 0.5 mol/L two-
Table 1
Scoring System with Combination of Morphologic and Dynamic Parameters for
Evaluation of Breast Lesions on Contrast-enhanced MR Images
Criterion Score
Shape
Round, oval, lobular 0
Linear, ductal, segmental, dendritic, spiculated 1
Margins
Regular 0
Irregular 1
Kinetic pattern
Initial enhancement*
50% 0
50 and100% 1
100% 2
Postinitial enhancement
Continuous† 0
Plateau‡ 1
Washout§ 2
Enhancement pattern
Homogeneous 0
Inhomogeneous 1
Rim 2
Source.—References 38, 39.
Note.—Total score interpretation and translation into BI-RADS categories 1–5 is as follows: no detectable enhancement  no
enhancing focus  BI-RADS 1, score 0–2  benign  BI-RADS 2, score 3  probably benign  BI-RADS 3, score 4–5 
suspicious  BI-RADS 4, and score 6–8  highly suggestive of malignancy  BI-RADS 5.
* Initial peak signal intensity within the first 3 minutes after contrast agent administration, relative to the signal intensity at
unenhanced imaging.
† Continuous signal intensity is defined as when a progressive signal intensity increase is found during the 4th, 5th, and 6th
minutes and the signal intensity at the 6th minute is greater than 10% of that of the initial peak signal intensity obtained during
the 1st, 2nd, and 3rd minutes.
‡ Plateau is defined as when the postinitial signal intensity during the 4th, 5th, and 6th minutes remains within the range of
10% of that of the initial peak signal intensity obtained during the 1st, 2nd, and 3rd minutes.
§ Washout is defined as when a progressive signal intensity decrease is found during the 4th, 5th, and 6th minutes and the
signal intensity at the 6th minute is less than 10% of that of the initial peak signal intensity obtained during the 1st, 2nd, and
3rd minutes.
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compartment gadolinium chelates (ga-
dopentetate dimeglumine, Magnevist,
Schering, Berlin, Germany; gadoterate
meglumine, Dotarem, Guerbet, Paris,
France; gadodiamide, Omniscan, Am-
ersham Health, Oslo, Norway; or gado-
teridol, ProHance, Bracco, Milan, Italy)
was intravenously administered at the
rate of 2 mL/sec by using an automatic
injector. Injection was followed by flush-
ing with 20 mL of saline. Taking into
account that the central lines of the k-
space, mainly devoted to image contrast
resolution, were acquired in the central
third of the sequence time duration, the
contrast agent injection was started at
the same time as the first contrast-en-
hanced sequence was started. The num-
ber of contrast-enhanced sequences,
typically five with a temporal resolution
of 90 seconds, was sufficient to obtain
dynamic information during at least the
first 6 minutes after contrast agent in-
jection.
Temporal subtraction (enhanced
minus unenhanced images) was always
performed for the first, second, and last
contrast-enhanced sequences, and a
maximum intensity projection algo-
rithm was applied for the first and the
second contrast-enhanced sequences.
Signal intensity–time and percentage of
enhancement–time dynamic curves were
obtained for targeted small regions of in-
terest positioned on the areas of homoge-
neous maximal enhancement within the
enhancing lesion (37). Source and pro-
cessed images were electronically stored
on compact discs. Twenty-eight radiolo-
gists interpreted the contrast-enhanced
MR images from breast examinations in
the 17 centers.
Morphologic and dynamic parame-
ters were combined according to the
criteria first defined by Fischer et al (38)
and tested by Baum et al (39) in 1031
breasts. In the study by Baum et al,
sensitivity and specificity were both
92%. This eight-level scoring system
was modified into a five-point scale ac-
cording to the BI-RADS (40) classifica-
tion (Table 1).
Work-up of Lesions Suspicious for
Malignancy and Pathologic Standard of
Reference
An integration across the modalities
was performed at each center after
each physician had reported findings for
CBE, mammography, US, and contrast-
enhanced MR imaging. In patients who
had a palpable breast nodule that was
indeterminate or suspicious for malig-
nancy or an imaging-detected lesion
classified as BI-RADS 4 or 5 with one or
more than one of the three modalities,
fine-needle aspiration or core-needle
(14-gauge) biopsy was performed. When
the lesion was detectable at US (at the
first look before contrast-enhanced MR
imaging or at the second look after con-
trast-enhanced MR imaging), the biopsy
was performed with US guidance.
When the lesion was mammographi-
cally detectable and not detectable at
US, the biopsy was performed with ste-
reotactic guidance. When the lesion
was detectable at only contrast-en-
hanced MR imaging (which included a
Table 2
Multimodality Surveillance of 278 Women at High Risk of Breast Cancer: Enrollment and Detection Rate per Year
Population Characteristics Enrolled Detection Rate per Year*
Enrollment
BRCA1 mutation carriers 98 (35.3) 7/142 (4.9)†
BRCA2 mutation carriers 68 (24.5) 4/103 (3.9)†
First-degree relatives of BRCA1 or BRCA2 mutation carriers 9 (3.2) 0/13 (0)
Overall no. of BRCA1 or BRCA2 mutation carriers and first-degree relatives of BRCA1 or BRCA2 mutation carriers 175 (62.9) 11/258 (4.3)‡
Strong family history of breast cancer and/or ovarian cancer§ 103 (37.1) 7/119 (5.9)‡
Overall no. of women who underwent screening 278 (100) 18/377 (4.8)
Previous vs no previous breast cancer and/or ovarian cancer
Women with previous personal breast cancer and/or ovarian cancer 123 (44.2) 9/169 (5.3)#
Women without previous personal breast cancer and/or ovarian cancer 155 (55.8) 9/208 (4.3)#
Note.—Data are numbers of women, and numbers in parentheses are percentages. All 278 enrolled women underwent first-round multimodality evaluation, whereas only 99 of them underwent
second-round evaluation (44 BRCA1 mutation carriers, 35 BRCA2 mutation carriers, four first-degree relatives of a BRCA1 mutation carrier, no first-degree relatives of a BRCA2 mutation carrier,
and 16 women enrolled on the basis of a strong family history of breast cancer and/or ovarian cancer).
* The detection rate per year was calculated for each subset and overall as the ratio between the number of patients who were affected by breast cancer during the first or second round and the
number of women who underwent screening at the first round plus the number of women who underwent screening at the second round.
† The difference in the detection rate between BRCA1 mutation carriers and BRCA2 mutation carriers was not significant (2 test).
‡ The difference in the detection rate between BRCA1 or BRCA2 mutation carriers or first-degree relatives of a BRCA1 or BRCA2 mutation carrier and women enrolled on the basis of a strong family
history of breast cancer and/or ovarian cancer was not significant (2 test).
§ Subjects with a strong family history of breast cancer and/or ovarian cancer had first- or second-degree relatives in either the maternal or the paternal line who had at least three female breast
cancers in those younger than 60 years, at least three female breast cancers in those younger than 60 years and/or ovarian cancer at any age, or at least three female breast cancers in those younger
than 60 years and/or male breast cancer at any age.
 Of 123 enrolled patients with previous breast cancer and/or ovarian cancer, 104 had a previous breast cancer, 14 had a previous ovarian cancer, and five had a previous breast cancer and ovarian
cancer; seven of these patients with previous breast and/or ovarian cancer had had an inconclusive genetic test (ie, negative for BRCA1 or BRCA2 mutations [BRCAX status]).
# The difference in the detection rate between women with a previous personal breast cancer and/or ovarian cancer versus women without a previous personal breast cancer and/or ovarian cancer
was not significant (2 test).
BREAST IMAGING:Multicenter Multimodality Surveillance Sardanelli et al
702 Radiology: Volume 242: Number 3—March 2007
second-look US examination with a
negative image), biopsy and presurgi-
cal localization were performed with
contrast-enhanced MR imaging guid-
ance.
For any finding classified as BI-
RADS 3 (probably benign) at each imag-
ing modality without a higher classifica-
tion (ie, BI-RADS 4 or 5) at other diag-
nostic modalities in the same round, a
short-term (within 4 months) follow-up
with the same modality with which the
lesion was detected was planned. If the
finding was confirmed (ie, a lesion with
at least a BI-RADS 3 classification and
was not reduced in diameter), an imag-
ing-guided biopsy was performed ac-
cording to the protocol defined previ-
ously. When the report for the fine-nee-
dle or core biopsy indicated that the
lesion was suspicious for malignant dis-
ease or highly suggestive of malignancy,
the patient always underwent surgery.
When the findings in the report for the
fine-needle or core biopsy suggested a
diagnosis of lobular neoplasia (lobular
carcinoma in situ), atypical ductal hy-
perplasia, radial scar, papilloma, or
papillomatosis, the patient underwent
surgery, and pathologic examination of
the surgical specimen was performed.
For all the lesions classified as BI-RADS
4 or 5 at any imaging modality, the pa-
tient underwent surgery, and pathologic
examination was performed, even though
the fine-needle or core biopsy yielded a
negative, benign, or probably benign re-
sult.
All nonpalpable lesions were preop-
eratively localized by using a hook wire
or a charcoal suspension, with the guid-
ance of the imaging method used for
biopsy.
At the 17 centers, 19 pathologists
who had 9–35 years of experience with
breast pathology classified the patho-
logic specimens according to the 1981
World Health Organization breast can-
cer classification (41). The maximal di-
ameter of each malignant lesion was re-
corded. For invasive malignant lesions,
axillary nodal status was explored with
axillary dissection or sentinel lymph
node biopsy, depending on the prefer-
ence of each center involved in the
study.
Statistical Analysis
Overall detection rate per year was cal-
culated as the ratio between the number
of patients with pathologically proved
breast cancer and the sum of screening
events at the first and the second rounds
(278  99  377). The detection rate
for each round was calculated as the
ratio between the number of patients
with pathologically proved breast can-
cer at each round and the number of
women who underwent screening in the
same round. The detection rate per
year for subsets of enrolled women was
calculated as the ratio between the
number of patients who had a patholog-
ically proved breast cancer in the subset
of women and the number of screening
events in the members of the subset of
women in the analysis.
Sensitivity of each of the four modal-
ities was calculated as the ratio between
the number of true-positive findings
(pathologically proved breast cancer de-
tected by using each modality) and the
number of true-positive findings plus
false-negative findings (pathologically
proved breast cancer examined with the
same modality but not correctly diag-
nosed [ie, BI-RADS categories 1–3]).
For each modality, the false-negative
findings were defined as breast cancers
detected by using one, two, or three of
the remaining modalities and confirmed
at pathologic examination.
PPV of each of the four modalities
was calculated as the ratio between
true-positive findings (defined as previ-
ously mentioned) and the number of
true-positive findings plus false-positive
findings (findings that needed to be ex-
plored with invasive procedures that de-
fined a benign cytologic or pathologic
diagnosis). Invasive procedures in-
cluded fine-needle aspiration, core-nee-
dle biopsy, and surgical biopsy after im-
aging-guided localization (one patient
opted for bilateral prophylactic mastec-
tomy, which revealed a mammographic
finding as false-positive).
In the evaluation of multiple malig-
nant foci in the same breast, the total
number of malignant foci demon-
strated at pathologic examination was
used as the standard of reference. The
capability of each modality for depic-
tion of multiple malignant foci was
evaluated without considering the dif-
ference between multifocal and multi-
centric cancers.
For both sensitivity and PPV, 95%
confidence intervals were calculated
from the exact binomial distribution.
Differences in the mean age of the
enrolled women or patients and in the
mean pathologically determined diame-
ter of the tumors were tested by using
the two-tailed Mann-Whitney U test.
Differences in detection rate, percent-
age of patients with invasive cancer, and
percentage of patients with axillary
nodal metastatic involvement were
tested by using the 2 test or the Fisher
exact test, when the former was not
applicable—that is, for small samples
(fewer than 20 subjects sampled)—or
when one or more of the so-called ex-
pected values was smaller than five
(42). Statistical calculations were per-
formed by using a software package
(SPSS, version 6.0; SPSS, Chicago, Ill).
Figure 1
Figure 1: Flow diagram of the
multicenter surveillance of women
at high risk for breast cancer by
using contrast-enhanced MR
imaging, mammography, US, and
CBE.
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A difference with P  .05 was consid-
ered significant.
Results
Screening Population
The present interim analysis is based on
the data available in March 2004 at the
central data management unit in regard
to the first round for the first 278 en-
rolled subjects and the second round for
99 subjects (ie, the first 99 subjects who
underwent assessment in the second
round), for a total of 377 screening
events. The screening population (Table
2) consisted of 278 women (mean age,
46.0 years  12.0 [standard deviation];
range, 25–79 years) enrolled by 17 cen-
ters. All 278 women underwent assess-
ment in the first round and, until March
2004, 99 women participated in the sec-
ond round (35.6%). One hundred sev-
enty-five (63%) of 278 women were en-
rolled because they were BRCA1 or
BRCA2 mutation carriers or because
they were first-degree relatives of
BRCA1 or BRCA2 mutation carriers,
whereas 103 (37%) were enrolled on
the basis of family history, according to
the criteria stated before; seven of
them, all with a previous breast and/or
ovarian cancer, had an inconclusive ge-
netic test (BRCAX status).
Themean ages of patients enrolled by
using the two criteria stated previously
were 45.8 years  12.0 (175 women en-
rolled because they were BRCA1 or
BRCA2 mutation carriers or first-degree
relatives of BRCA1 or BRCA2 mutation
carriers) and 46.5 years  12.0 (103
women enrolled on the basis of the family
history), and there was no significant dif-
ference (Mann-Whitney U test) in mean
age between them. In particular, the
mean age of BRCA1 mutation carriers or
first-degree relatives of BRCA1 mutation
carriers was 45.7 years  11.9, whereas
the mean age for the analogous BRCA2
group was 45.9 years  12.3, and there
was no significant difference (Mann-
Whitney U test) in mean age between the
groups. Of 278 women who underwent
screening, 123 (44.2%) had had previous
breast and/or ovarian cancer and 155
(55.8%) had not had these conditions;
the mean ages at entry were 50.4 years
11.5 for those who had had previous can-
cer and 42.6 years  11.3 for those who
had not had previous cancer; the differ-
ence between the groups was significant
(P  .001, Mann-Whitney U test). The
mean number of enrolled women per
center was 16.3 (range, 4–62). The dis-
tribution among the centers was as fol-
lows: nine centers, four to 10 enrolled
women; five centers, 11–30 enrolled
women; and three centers, more than 30
enrolled women. For each of the 377
screening events, four examinations
(CBE, mammography, US, and contrast-
enhanced MR imaging) were performed
on the same day (n 347), during 1 week
(n  1), during 2 weeks (n  15), during
3 weeks (n 2), during 4 weeks (n 2),
during 5 weeks (n  1), during 6 weeks
(n  2), during 7 weeks (n  2), and
during 8 weeks (n 5). All theMR exam-
inations of fertile womenwere performed
on the 7th–14th day of the menstrual cy-
cle. A flow diagram of the entire study is
presented in Figure 1.
Cancer Detection
Of 278 women who underwent screen-
ing at the first round, we found 11 pa-
tients with cancer (detection rate,
4.0%), whereas of 99 women who un-
derwent screening at the second round,
we found seven patients with cancer
(detection rate, 7.1%), and the differ-
ence in rates was not significant (2
test). The overall detection rate was
4.8% (18 of 377). The detection rates
for enrollment criteria and presence or
absence of personal history of breast or
ovarian cancer are presented in Table 2.
The overall maximal pathologically
determined mean diameter was 13.3
mm  8.2, and eight of 18 patients had
tumors 10 mm or smaller in diameter.
Fourteen patients had at least one inva-
sive cancer and four patients had only in
situ cancers; considering the largest tu-
mor for each patient in both groups, the
mean diameter was 15.8 mm  7.6 for
the invasive cancers and 4.8 mm  1.7
for the in situ cancers. Nine (50%) of 18
patients had multifocal, multicentric, or
bilateral breast cancers. When we con-
sidered the most aggressive lesion in the
nine patients with multifocal, multicen-
tric, or bilateral cancers, we observed a
percentage of patients with invasive
cancers of 78% (14 of 18) (Table 3).
No interval cancer was reported.
The sensitivity of contrast-enhanced
MR imaging, mammography, and US is
shown in Table 4. Mammography,
which was not performed in one pa-
tient, aided in the diagnosis of a cancer
in five (63%) of eight patients with 50%
or less of the breast occupied by fi-
broglandular density and in five (56%)
of nine patients with more than 50% of
the breast occupied by fibroglandular
density, and the difference was not sig-
nificant (Fisher exact text); the only
false-negative finding at contrast-en-
hanced MR imaging was in a breast with
fibroglandular density that extended
into more than 50% of the breast on the
mammograms. Examples of a three-mo-
dality true-positive finding and of a find-
ing that was true-positive only at con-
trast-enhanced MR imaging are shown
in Figures 2 and 3. The false-negative
finding at contrast-enhanced MR imag-
ing is shown in Figure 4.
Of 18 patients in whom breast can-
Table 4
Patient-based Sensitivity and PPV of Contrast-enhanced MR Imaging, Mammography,
US, and CBE in Multimodality Surveillance for Breast Cancer in 278 High-Risk Women
Modality
Sensitivity (%) PPV (%)
Value 95% CI Value 95% CI
Contrast-enhanced MR imaging 93.8 (15/16) 71.7, 98.9 62.5 (15/24) 42.7, 78.8
Mammography 58.8 (10/17) 36.0, 78.4 76.9 (10/13) 49.7, 91.8
US 64.7 (11/17) 41.3, 82.7 64.7 (11/17) 41.3, 82.7
CBE 50.0 (9/18) 29.0, 71.0 81.8 (9/11) 52.3, 94.9
Note.—Numbers in parentheses were used to calculate the percentages. CI  confidence interval.
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cer was detected, 11 had been enrolled
on the basis of genetic testing and seven
had been enrolled only on the basis of a
strong family history of breast cancer
and/or ovarian cancer. No significant
difference was observed between the
mean age of the seven BRCA1 muta-
tion carriers with breast cancer (53.7
years 8.3) and that of the four BRCA2
mutation carriers (48.8 years  16.3)
(Mann-Whitney U test), with a mean
age of patients with BRCA1 and BRCA2
of 51.9 years 11.3 (Table 5). In the 18
patients who presently had breast can-
cer, nine (50%) had palpable tumors
and nine (50%) had nonpalpable tu-
mors (Tables 6, 7).
In the 18 patients who had breast
cancers, six (33%) cancers were de-
tected only with contrast-enhanced MR
imaging. None of the cancers were de-
tected only with CBE, only with mam-
mography, or only with US (Table 8).
Detection of Multiple Malignant Foci in
Patients with Invasive Cancers
When we considered the six patients
with invasive cancers and multiple
malignant foci per breast, we ob-
served seven breasts with multiple
Figure 2
Figure 2: Asymptomatic 52-year-old woman with a strong family history of breast cancer that included a personal previous invasive ductal carcinoma of the right
breast at 50 years of age had no suspicious finding at CBE. (a)Mediolateral oblique, (b) craniocaudal, and (c)magnified craniocaudal mammographic views of the right
breast show a suspicious opacity with irregular borders associated with microcalcifications in central location (arrow on a and b). Less than 50% of the breast was occu-
pied by fibroglandular density. Microcalcifications were confirmed with magnified spot compression (arrow on c). At first-look (ie, prospective) US examination (10-
MHz probe), not shown, no suspicious findings were detected. (d)Second-look US scan (10-MHz probe) at final assessment showed hypoechoic suspicious mass (ar-
row) at same location as mammographic finding. (e)Coronal-subtracted (first enhanced minus unenhanced) contrast-enhanced T1-weighted gradient-echo MR image
(repetition time msec/echo time msec, 11/4.8; flip angle, 25°; section thickness, 1 mm; matrix, 192 384; field of view, 192 384 mm) obtained with 0.1 mmol/kg
gadoterate meglumine. (f)Percentage of enhancement–time dynamic curve for enhancing focus shown on c. (g)Coronal maximum intensity projection of both breasts
shows spiculated enhancing focus in central location (arrow on e) associated with a strong initial enhancement with postinitial washout, visible on f. On the maximum
intensity projection, the central lesion is well depicted (white arrow), whereas a second smaller enhancing focus 3 cm below (open arrow) is visible (percentage of en-
hancement–time dynamic curve with an initial enhancement greater than 100% and postinitial washout not shown) but was not detected at mammography and US. Note
the prominent vascular supply of both lesions (arrowheads on g). Pathologic findings at mastectomy revealed bifocal invasive ductal carcinoma of 10 mm in diameter for
one lesion (white arrow) and of 6 mm in diameter for the other (open arrow) of both lesions. At mammography, two other small masses were observed in both projections
(a, b). They were known benign nodules that were unchanged in comparison with previous mammograms.
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foci. At CBE, the diagnosis of generi-
cally multiple palpable nodules was
that they were suspicious for malig-
nancy in one breast; the wrong diag-
nosis of unifocal cancer was deter-
mined in two breasts, and the diagno-
sis of all malignant lesions was missed
in four. At mammography, underesti-
mation of the number of malignant
foci in one breast occurred, the wrong
diagnosis of unifocal cancer was deter-
mined in four breasts, and the diagno-
sis of all malignant lesions was missed
in two breasts. US, which was not per-
formed in one patient with unilateral
bifocal cancer, aided in the identifica-
tion of the exact number of malignant
foci in two breasts, contributed to un-
derestimation of the number of malig-
nant foci in one breast, and led to the
wrong diagnosis of unifocal cancer in
three breasts. At contrast-enhanced
MR imaging, the number of malignant
foci was correctly identified in four
breasts and was underestimated in
one breast, and the wrong diagnosis of
unifocal cancer was determined in one
breast. Moreover, contrast-enhanced
MR imaging was the only technique
that depicted a second focus of inva-
sive lobular carcinoma, although it
failed in the characterization of both
foci as malignant (Table 3, patient 15).
Thus, the percentage of breasts with
an exact detection of the number of
malignant foci was 0% (zero of seven)
for CBE and mammography, 33% (two
of six) for US, and 71% (five of seven)
for contrast-enhanced MR imaging.
False-Positive Diagnoses and PPVs
A total of 15 invasive procedures were
performed in 13 patients without breast
cancer who had a mean age of 43.9
years 10.3; five of them were enrolled
because they were BRCA1 mutation
carriers, one was enrolled as a first-
degree relative of a BRCA1 mutation
carrier, and seven were enrolled be-
cause of a strong family history of breast
and/or ovarian cancer. Only two of
them had a previous personal history of
breast cancer. The following 20 false-
positive findings led to invasive diagnostic
procedures: two at CBE, three at mam-
mography, six at US, and nine at contrast-
Figure 3
Figure3: Asymptomatic69-year-oldBRCA1 carrierwithprevious leftmastectomy for invasiveductal carcinomaat55
yearsoldhadnosuspiciousfindingatCBEof rightbreast. (a)Mediolateraland (b)craniocaudalmammographicviewsof
rightbreastwithoutanydetectedsuspiciousabnormality; less than50%ofbreastwasoccupiedbyfibroglandulardensity.
NosuspiciousfindingwasdetectedatUS(notshown). (c)Transverseand (d) lateralmaximumintensityprojectionsof
subtracted(firstenhancedminusunenhanced)coronalT1-weightedgradient-echocontrast-enhancedMRimages(8.9/
4.3,25°flipangle)afteradministrationof0.1mmol/kggadopentetatedimeglumine.Twosmallenhancingsuspiciousfoci
(solidarrowsoncandd)arevisibleonthe lateralquadrantsof therightbreast. (e)Transverse fastspin-echoMRimaging–
guided(204/20,90°flipangle)biopsyofoneof the twofociconfirmedpresenceofamalignant lesion.Arrowshowsthe
amagneticneedle,with the tipat thesiteof theenhancingfocus.Pathologicexaminationof thebreastaftermastectomy
demonstratedmultiple fociofductalcarcinomainsitu(maximumdiameter,3mm); twowere locatedwhereMRimaging
showedenhancinglesions. In the innerposteriorpartof thebreast, the transverseMRsubtractedmaximumintensitypro-
jectionimageshowsenhancementcausedbythesuperimpositionof internalmammaryvessels(openarrowonc).
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enhanced MR imaging. Because three
invasive diagnostic procedures were
determined with a concordant false-
positive finding at two modalities and
one invasive diagnostic procedure was
determined with a concordant false-
positive finding at three modalities, 20
false-positive findings led to only 15
invasive diagnostic procedures. These
15 invasive procedures were US-
guided fine-needle aspiration or core-
needle biopsy (n  11), US-guided
fine-needle aspiration and local exci-
sion (n  2), fine-needle aspiration
with mammographic stereotactic guid-
ance (n  1), and mastectomy (n  1).
The woman who underwent mastec-
tomy decided to undergo bilateral pro-
phylactic mastectomy, which did not
reveal any malignant lesions at patho-
logic examination; thus, one false-pos-
itive finding occurred at mammogra-
phy. Of the 11 US-guided procedures,
seven were performed as the result of
second-look US findings detected only
with contrast-enhanced MR imaging.
The cytologic or pathologic benign diag-
nosis obtained with these 15 invasive
procedures included one or two of the
following findings: single or multiple fi-
broadenomas (n  4), papilloma (n 
2), adenosis or fibroadenosis (n  2),
intraparenchymal lymph node (n  1),
and fibrocystic changes or other benign
findings (n 8). On this basis, we calcu-
lated the PPVs (Table 4).
Discussion
The detection rate for breast cancer in
high-risk women (in our study, 4.8%)
was more than 10-fold that obtained in
the screening of a general female popu-
lation. The first-screening detection
rate recently reported by Caines et al
(43) by using mammography in the gen-
eral female population was 0.37% for
women aged 40–49 years and 0.58%
Figure 4
Figure 4: Asymptomatic 56-year-old woman with a strong family history of breast cancer. (a)Craniocaudal mammographic view shows asymmetric opacity (arrow) in
left breast (fibroglandular density greater than 50%). (b)US scan shows hypoechoic mass (arrow) of 3 mm in diameter with partly irregular borders. Both mammogram
and US scan were judged as suggestive of malignancy. (c, e) Two contrast-enhanced coronal subtracted (first enhanced minus unenhanced) T1-weighted gradient-echo
MR images (8/4, 25° flip angle, 2.5-mm section thickness; 128 256 matrix; 175 350-mm field of view) obtained after administration of 0.1 mmol/kg gadopentetate
dimeglumine. Each shows a round enhancing lesion (arrow). (d, f)Percentage of enhancement–time dynamic curves show continuous increase. Both enhancing lesions
were judged as benign at MR imaging. Pathologic examination revealed two foci of invasive lobular carcinoma of 3 and 9 mm in diameter.
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for women aged 50–59 years. We be-
lieve our high detection rate was caused
by not only the high disease prevalence
in the population but also the multimo-
dality approach, which included con-
trast-enhanced MR imaging. In fact, in
the trial by Brekelmans et al (44) in
which patients underwent yearly screen-
ing mammography and CBE every 6
months, the detection rate in BRCA1
and BRCA2 mutation carriers was
3.3%.
More important, we found no signif-
icant difference in detection rate in
BRCA1 and BRCA2 mutation carriers
or first-degree relatives of BRCA1 or
BRCA2 mutation carriers compared
with that in women enrolled only on the
basis of a strong family history of breast
cancer and/or ovarian cancer. The com-
parison between the cancers detected
in the two groups of women enrolled
according to these two selection criteria
revealed no significant differences in
terms of patients’ ages, tumoral patho-
logic features, and axillary nodal in-
volvement. This lack of a significant dif-
ference is due to the strict criteria we
adopted for including women on the ba-
sis of only the family history and it also
explains our high detection rate (4.8%).
This detection rate is identical to that
obtained in the study by Warner et al
(26), who included only BRCA1 and
BRCA2 mutation carriers, with 39% of
women with personal previous breast
cancers; that percentage was 44% in
our study.
In breast cancer screening pro-
grams for the general female popula-
tion, women with a previous personal
history of breast cancer are frequently
excluded. This approach is under dis-
cussion (28) because no consensus ex-
ists about the duration and frequency of
follow-up in women treated for breast
cancer or about the schedule of exami-
nations, particularly those at 5 years af-
ter the primary treatment (45). In our
study, nine (50%) of 18 patients who
had a newly diagnosed breast cancer
were women with a previous personal
history of breast cancer, and the detec-
tion rate was 5.3%, which was not sig-
nificantly different from the detection
rate (4.3%) found in women without a
previous personal breast cancer and/or
ovarian cancer.
In women with familial-genetic pre-
disposition to the disease, the risk of
developing a contralateral breast cancer
or an ovarian cancer within 5 years af-
ter a previous tumoral event is esti-
mated to be between 30% and 60%
(4,46). Moreover, the inclusion of
women with previous personal breast
cancer and/or ovarian cancer is the
probable reason for our relatively
higher mean age at entry for the screen-
ing population (46 years) when we com-
pared that age with the age in two other
studies in which women with a personal
history of previous breast cancer were
excluded (25,27). In both of the studies,
the mean or median age was 40 years.
On the other hand, in the study by
Warner et al (26), the percentage of
women with a personal history of breast
cancer was 39%, which is close to our
percentage of 44%, and the reported
mean age was 47 years.
Of the 11 patients genetically tested
Table 5
Comparison between 11 BRCA1 and BRCA2 Mutation Carriers and Seven Women
Enrolled on the Basis of a Strong Family History of Breast Cancer and/or Ovarian
Cancer in 278 High-Risk Women
Clinical Data Group A Group B
Patient age (y) 51.9 11.3 49.9 8.8
Diameter at pathologic examination (mm) 14.1 9.4 12.1 6.4
Invasive breast cancers* 9 (82) 5 (71)
Pathologic grade of cell differentiation 2.4 0.8 2.5 0.7
Multifocal, multicentric, or bilateral cancers* 4 (37) 5 (71)
Axillary nodal involvement* 1 (9) 2 (29)
Note.—Group A included 11 women who were BRCA1 and BRCA2 mutation carriers who had cancer, and group B included
seven women with a strong family history of breast cancer and/or ovarian cancer who had cancer. Data are the mean 
standard deviation except where otherwise specified. The Fisher exact test was used for comparisons between percentages,
and the Mann-Whitney U test was used for comparisons between patients’ ages, between tumoral diameters at pathologic
examinations, and between pathologic grades of cell differentiation. Differences between group A and group B were not
significant.
* Data are numbers of women, and numbers in parentheses are percentages.
Table 6
Comparison between Nine Patients with Palpable Cancers and Nine Patients with
Nonpalpable Cancers Detected in Multimodality Screening in 278 Women at
Genetic-Familial High Risk for Breast Cancer
Clinical Data Group A Group B
Patient age (y) 47.2 9.1 55.0 10.2
Diameter at pathologic examination (mm) 19.0 6.9 7.7 4.8
Invasive breast cancers* 9/9 (100) 6/9 (67)
Pathologic grade of cell differentiation 2.7 0.7 2.1 0.8
Multifocal, multicentric, or bilateral cancers* 3/9 (33) 6/9 (67)
Axillary nodal involvement* 2/8 (25) 1/10 (10)
Note.—Group A included nine patients with palpable cancers, and group B included nine patients with nonpalpable cancers.
Data are the mean  standard deviation except where otherwise specified. Of the nine patients with palpable cancers, one
with marked anxiety did not undergo MR imaging, one had indeterminate results of MR imaging because of movement
artifacts, and one with breast implants did not undergo successful mammography because of marked discomfort during
compression. Of the nine patients with nonpalpable cancers, one did not undergo US for unspecified reasons. The Fisher exact
test was used for comparisons between percentages, and the Mann-Whitney U test was used for comparisons between
patients’ ages, between tumoral diameters at pathologic examination, and between pathologic grades of cell differentiation.
Differences between group A and group B were not significant except for diameter at pathologic examination (P  .002).
* Data are numbers of women, and numbers in parentheses are percentages.
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in whom breast cancer was detected,
seven were BRCA1 mutation carriers
and four were BRCA2 mutation carri-
ers. The relatively advanced mean age
of the BRCA1 and BRCA2mutation car-
riers (53.7 years 8.3 and 48.8 years
16.3, respectively) and the higher age
(even though not significantly different)
of the BRCA1 group can be explained by
the presence of patients with a personal
history of previous breast cancer in
both groups: five (71%) of seven in the
BRCA1 mutation carrier group and one
(25%) of four in the BRCA2 mutation
carrier group.
The mean tumoral diameter at
pathologic examination was 13.7 mm 
8.6, and eight (44%) of 18 patients had
tumors of 10 mm or smaller in diame-
ter; the percentage of patients with tu-
mors of that diameter was similar to the
percentage reported by other authors,
and the percentages ranged from 43%
to 55% (25–27). This result appears to
be interesting if we consider that the
tumor volume doubling time of invasive
cancers is shorter in BRCA1 or BRCA2
mutation carriers than it is in noncarri-
ers, as recently reported (ie, 45 days for
carriers and 84 days for noncarriers)
(47).
The high percentage (78%) of inva-
sive cancers in our study is in agree-
ment with data in previous studies; in
those studies, the researchers reported
a percentage from 73% (26) to 88%
(25). Our percentage of cancers with a
pathologic grade of cell differentiation
of 3 (10 of 18, 56%) is slightly lower
than that reported in two previous stud-
ies about high-risk women; in those
studies, this percentage was 66% (27)
and 67% (24). Interestingly, Kriege et al
(25), who included a large proportion of
women with a lower risk of breast can-
cer (starting from only a 15% of lifetime
risk) in their study, reported a percent-
age of grade 3 cancers of only 37%.
On the other hand, of 13 patients
with invasive cancers in whom the axil-
lary nodal status was explored, we had
only three patients with nodal cancer
involvement (23%), confirming the pos-
sibility of an early diagnosis in terms of
nodal involvement in high-risk women,
as already found in other studies in
which the percentages of invasive can-
cers with known nodal status and meta-
static involvement ranged from 0% (24)
to 21% (25). For comparison, we
should consider that several screening
studies of high-risk women by using
mammography without contrast-enhanced
MR imaging have shown an incidence of
positive nodes of 30%–45% (44,48,49).
The absence of interval cancer in
our series must be related to the small
number of screening events per woman
(only 1.4) considered in this report and
to a limited follow-up. The higher detec-
tion rate at the second round, which
was 7.1% and was greater but not sig-
nificantly higher than 4.0% at the first
round, confirms that in high-risk women
we should adjust some conceptual tools
used in mammographic screening of the
general female population. For in-
stance, the typical difference between
“prevalent” cancers of the first screen-
ing and “incident” cancers of subse-
quent screenings was not observed in
our study. Similar results were reported
by Warner et al (26), who described a
detection rate of 5.5% at the first round
and 5.1% at the second round. This
finding is probably related to the high
speed of tumoral growth of breast can-
cer in high-risk women (26,47).
Our study findings indicate that con-
trast-enhanced MR imaging may enable
the detection of unsuspected breast
cancers by using other diagnostic mo-
dalities in women at genetic-familial
high risk, as already reported in other
studies (23–27). In our study, the high
sensitivity of 94% for contrast-en-
hanced MR imaging could be related to
the lower number of screening events
Table 7
Patient-based Sensitivity of Contrast-enhanced MR Imaging, Mammography, and US
for Palpable and Nonpalpable Breast Cancers in Multimodality Screening in 278
Women at Genetic-Familial High Risk for Breast Cancer
Modality
Sensitivity for Palpable
Cancers (%)
Sensitivity for Nonpalpable
Cancers (%)
Contrast-enhanced MR imaging 100.0 (7/7) 88.9 (8/9)
Mammography 87.5 (7/8) 33.3 (3/9)
US 100.0 (9/9) 25.0 (2/8)
Note.—Numbers in parentheses were used to calculate the percentages.
Table 8
Comparison between 12 Patients with Tumors Detected with a Combination of CBE,
Mammography, and/or US and Six Patients with Tumors Detected Only with
Contrast-enhanced MR Imaging in 278 High-Risk Women
Clinical Data Group A Group B
Patient age (y) 48.6 8.2 56.2 12.5
Diameter at pathologic examination (mm) 18.0 7.3 5.2 1.5
Invasive cancers* 11 (92) 3 (50)
Pathologic grade of cell differentiation 2.5 0.7 2.0 1.0
Multifocal, multicentric, or bilateral cancers* 6 (50) 3 (50)
Axillary nodal involvement* 2 (17) 1 (17)
Note.—Group A included 12 patients with tumors detected with a combination of CBE, mammography, and US, and group B
included six patients with tumors detected only with contrast-enhanced MR imaging. For group A, of the 12 tumors, 11 were
true-positive and one was false-negative at MR imaging. Data are the mean  standard deviation except where otherwise
specified. The Fisher exact test was used for comparisons between percentages, and the Mann-Whitney U test was used for
comparisons between ages, between tumoral diameters at pathologic examination, and between pathologic grades of cell
differentiation. The differences between group A and group B were not significant except for diameter at pathologic
examination (P  .001). For invasive cancers, P  .078.
* Data are numbers of patients, and numbers in parentheses are percentages.
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per woman, which was 1.4 without in-
terval cancers, when we compared
these values with those in the study by
Kriege et al (sensitivity, 71%; screening
events per woman, 2.7; interval can-
cers, four) (25). In both the study by
Warner et al (26) and the Magnetic Res-
onance Imaging in Breast Screening
study by Leach et al (27), the research-
ers reported a sensitivity of 77% for
contrast-enhanced MR imaging. Warner
et al reported 1.9 screening events per
woman with only one interval cancer,
and Leach et al reported 3.0 screening
events per woman with two interval
cancers. Kuhl et al (24), however, re-
ported a sensitivity of 100% and 1.9
screening events per woman without in-
terval cancers. On the other hand, if the
indeterminate MR result caused by arti-
facts from the patient’s movements is
considered false-negative, we obtained
a sensitivity of 88% (15 of 17). In this
patient, however, contrast-enhanced
MR imaging was not repeated because
we had a concordant positive result
with CBE, mammography, and US.
We did not observe a higher prev-
alence of palpable cancers at the first
round: The percentage of palpable
cancers was 36% (four of 11) at the
first round and 57% (four of seven) at
the second round. Palpability was
clearly related to the mean tumoral
diameter (19.0 mm  6.9 for nine pal-
pable cancers vs 7.7 mm  4.8 for
nine nonpalpable cancers), and this
high percentage of palpable cancers
could be related to the rapid tumoral
growth in these patients (47). We con-
firm the insufficient sensitivity of CBE
in high-risk women, as already re-
ported (24–26).
The range of sensitivity values
(88%–100%) for palpable cancers among
the three imaging modalities in our
study compared with that for nonpal-
pable cancers (33% for mammography,
25% for US, and 89% for contrast-en-
hanced MR imaging) shows that the ad-
vantage of contrast-enhanced MR imag-
ing is in the detection of small nonpal-
pable cancers. It should be emphasized
that the mean age of patients in whom
cancers were detected with only con-
trast-enhanced MR imaging was 56.2
years  12.5, and this age is relatively
more advanced, even though it is not
significantly higher than the mean age of
48.6 years  8.2 in women in whom
diagnosis was determined with a combi-
nation of CBE, mammography, and US.
In other words, we do not have evi-
dence to advocate a gain in sensitivity
by using contrast-enhanced MR imaging
only in younger premenopausal high-
risk women and not in older postmeno-
pausal high-risk women. Also, the
breast density pattern does not seem to
play a key role, as shown by the similar
low sensitivity for mammography in
both breasts with fibroglandular density
of 50% or less (five of eight, 63%) and
breasts with fibroglandular density
greater than 50% (five of nine, 56%).
Moreover, the possible overdiagnosis
because of the high sensitivity of con-
trast-enhanced MR imaging is counter-
balanced by the fact that five of six pa-
tients in whom breast cancer was diag-
nosed during the study only with
contrast-enhanced MR imaging had an
invasive or multifocal, multicentric, or
bilateral cancer.
The PPV of 63% for contrast-en-
hanced MR imaging in our experience is
very close to that of 64% reported by
Kuhl et al (24) and higher than that of
46% reported byWarner et al (26). Our
performance can be related to the use of
a model of interpretation of contrast-
enhanced MR images in which both
morphologic and dynamic parameters
are integrated in a simple score (38,39),
which can be easily translated into one
of the BI-RADS categories of 1–5. The
key point is that, with this scoring sys-
tem, a round, oval, or lobular homoge-
neously enhancing lesion with regular
margins, less than 100% initial en-
hancement, and a continuous or plateau
postinitial enhancement (or with an ini-
tial enhancement of 100% or greater
and a continuous postinitial enhance-
ment) is considered benign. We paid a
trade-off for this criterion: The only
false-negative finding at contrast-en-
hanced MR imaging was an invasive lob-
ular carcinoma that was diagnosed as
benign. Sensitivity, however, remained
as high as 94%, and a good balance with
PPV (63%) was obtained. Nevertheless,
it is important to realize that our results
(in particular the PPV of 63% for con-
trast-enhanced MR imaging in a screen-
ing setting) were obtained in a very
high-risk population and that the same
protocol in a lower-risk population
could have a lower performance.
Our PPV for mammography (77%)
is within the range of values in similar
studies: from 30% (24) to 89% (26).
We observed a higher PPV for US
(65%) if one compares the PPV with
that of 29% from one previous study
(26) and also a higher PPV for CBE
(82%) if one compares the PPV with
those of 18% (25) and 50% (26) from
two previous studies.
The first general limitation of our
study was the nonrandomized study de-
sign. We do not know whether an inten-
sive screening protocol (including con-
trast-enhanced MR imaging) is able to
provide an effect in terms of saved years
of life in such high-risk women. Such a
question could be answered with ran-
domized trials, although we agree with
the ethical concerns recently raised
about this possibility (50).
The second important limitation
was the small number of screening
events per woman considered in the
study (99 women for the first and sec-
ond rounds and 179 women for only the
first round, for a total of 377 screening
events and a mean of 1.4 screening
events per woman). We should con-
sider, however, that very few interval
cancers were reported in prospective
studies in which contrast-enhanced MR
imaging was used for the screening of
high-risk women: a total of seven inter-
val cancers versus 104 cancers detected
during the trials for 2956 women en-
rolled and 2.7 screening events per
woman (24–27).
The third limitation was that paired
statistical analysis of the diagnostic per-
formance of the modalities was not per-
formed. This comparison will be per-
formed at the end of the trial.
In conclusion, our interim experi-
ence suggests that contrast-enhanced
MR imaging is highly sensitive (94%) for
detection of breast cancer in multimo-
dality yearly surveillance—which also
includes CBE, mammography, and US—
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in high-risk women; moreover, the PPV
of contrast-enhanced MR imaging (63%)
is close to that of US (65%). In addition,
this multimodality approach allows an
early cancer diagnosis in terms of tumoral
size and nodal involvement. Further-
more, our data suggest that addition of
contrast-enhanced MR imaging to the
screening regimen may enable detection
of otherwise unsuspected breast cancer
not only in women who are BRCA1 and
BRCA2 mutation carriers but also in
women who meet strict criteria for a
strong family history of breast cancer
and/or ovarian cancer and that, in both
groups, women with a personal history of
breast cancer should be included. Finally,
our findings support the high sensitivity of
contrast-enhanced MR imaging of the
breast in the detection of multiple malig-
nant foci in high-risk women.
Acknowledgments: F.P. was responsible for
the project. F.S. operated radiological central
coordination. Data management was operated in
cooperation with A.V. and M.S.
Enrolling centers: The enrolling
centers, cities in which they are located,
and other persons who cooperated in
this study are as follows: Istituto Nazio-
nale per lo Studio e la Cura dei Tumori,
Milan: Silvana Bergonzi, Claudia Costa,
Claudio Ferranti, Monica Marchesini,
Gianfranco Scaperotta, Laura Suman,
Daniele Vergnaghi; Centro di Riferi-
mento Oncologico, Aviano: Riccardo
Dolcetti, Alessandra Viel, Silvia Ven-
turini; University of Modena and Reggio
Emilia, Modena: Renato Romagnoli,
Rachele Battista, Barbara Canossi, Mario
de Santis, Isabella Marchi, Veronica
Medici, Daniela Turchetti; University
Hospital of Ferrara, Ferrara: Patrizia
Querzoli; Ordine Mauriziano, Istituto
per la Ricerca e la Cura del Cancro,
Candiolo, Turin: Lisa Cellini, Laura
Martincich, Daniele Regge; University
of Pisa, Pisa: Carlo Bartolozzi, Gen-
eroso Bevilacqua, Isa Brunetti, Maria
Adelaide Caligo, Claudia Giaconi, Chi-
ara Iacconi, Dionisa Mazzotta, Monica
Moretti, Manuela Roncella; University
of Padua, Padua: Grazia Artioli, Emma
D’Andrea, Gianni Nardelli, Maria Or-
nella Nicoletto, Luigi Pescarini, Giorgio
Zavagno; Policlinico San Donato, San
Donato Milanese, Milan: Bijan Babaei,
Francesco Gerra, Adamo Magaldi, An-
drea Iozzelli, Eleonora N. Lupo, Michela
Russo; European Institute of Oncology,
Milan: Monica Barile, Luca Bazzi, Enrico
Cassano, Andrea Decensi, Massimo
Bellomi, Bernardo Bonanni, Irene Fe-
roce, Gaetano Villa; University of Udine,
Udine: Massimo Bazzocchi, Alexia Best-
agno, Giuliana Francescutti; Federico II
University, Naples: Matilde Pensabene,
Ida Capuano; San Martino University
Hospital, Genoa: Davide Brizzi; Univer-
sity of Chieti, Chieti: Pasquale Battista,
Alessandro Cama, Alessandro Carriero,
Renato Mariani-Costantini, Giandomenico
Palka; University of L’Aquila, L’Aquila:
Antonietta Ciccozzi, Franco Colista, Ca-
terina Fiumara, Silvia Lelli, Maria Man-
cini, Carlo Masciocchi, Enrico Ricevuto;
University of Trieste, Trieste: Antonio
Amoroso, Carla Dellach, Giorgio Mus-
tacchi, Roberto Pozzi-Mucelli; and Vita-
Salute University, San Raffaele Hospi-
tal, Milan: Angela De Gaspari, Isabella
Fedele.
Authors: The list of remaining au-
thors follows: Anna Cilotti, MD, Cosimo
Di Maggio, MD, Alfonso Fausto, MD,
Lorenzo Preda, MD, Chiara Zuiani,
MD, Alma Contegiacomo, MD, Antonio
Orlacchio, MD, Massimo Calabrese,
MD, Lorenzo Bonomo, MD, Ernesto Di
Cesare, MD, Maura Tonutti, MD, Pi-
etro Panizza, MD, and Alessandro Del
Maschio, MD.
Author affiliations: Unit of Radiol-
ogy, IRCCS Policlinico San Donato, San
Donato Milanese, Milan, Italy (A.F.);
Department of Cell Biology and Neuro-
sciences (G.D.) and National Center of
Epidemiology, Surveillance, and Health
Promotion (A.V., M.S.), Istituto Supe-
riore di Sanita`, Rome, Italy; Depart-
ments of Diagnostic Radiology 1 (R.M.,
G.T.) and Medical Genetics Service, Ex-
perimental Oncology (S. Manoukian),
Istituto Nazionale per lo Studio e la Cura
dei Tumori, Milan, Italy; Departments
of Radiology (S. Morassut) and Medical
Oncology (C.d.G.), Centro di Riferi-
mento Oncologico, Aviano, Italy; De-
partment of Oncology and Hematology,
University of Modena and Reggio Emilia,
Modena, Italy (M.F., L.C.); Breast Im-
aging Unit, University Hospital of Fer-
rara, Ferrara, Italy (S. Corcione); De-
partment of Diagnostic Radiology, Or-
dine Mauriziano, Istituto per la Ricerca
e la Cura del Cancro, Candiolo, Turin,
Italy (S. Cirillo, V.M.); Division of Diag-
nostic and Interventional Radiology, De-
partment of Oncology, Transplants, and
Advanced Technologies in Medicine,
University of Pisa, Pisa, Italy (A.
Cilotti); Section of Senology and Diag-
nostic Imaging, Department of Oncol-
ogy and Surgical Sciences, University of
Padua, Padua, Italy (C.D.M.); Depart-
ment of Radiology, European Institute
of Oncology, Milan, Italy (L.P.); Insti-
tute of Radiology, University of Udine,
Udine, Italy (C.Z.); Department of En-
docrinology and Molecular and Clinical
Oncology, Federico II University, Na-
ples, Italy (A. Contegiacomo); Depart-
ment of Radiology and Diagnostic Imag-
ing, General Hospital San Giovanni Cali-
bita Fatebene Fratelli, Rome, Italy
(A.O., now at the Department of Diag-
nostic Imaging and Interventional Radi-
ology, Tor Vergata University, Rome,
Italy); Department of Radiology, Uni-
versity of Genoa, Genoa, Italy (M.C.);
Department of Clinical Sciences and
Bioimages, University of Chieti, Chieti,
Italy (L.B., now at the Department of
Radiology, Catholic University, Rome,
Italy); Department of Radiology, Uni-
versity of L’Aquila, L’Aquila, Italy
(E.D.C.); Department of Radiology,
University of Trieste, Trieste, Italy
(M.T.); and Department of Radiology,
Vita-Salute University, San Raffaele
Hospital, Milan, Italy (P.P., A.D.M.).
Author contributions: Guarantors
of integrity of entire study, F.S., F.P.;
study concepts/study design or data ac-
quisition or data analysis/interpreta-
tion, all authors; manuscript drafting or
manuscript revision for important intel-
lectual content, all authors; manuscript
final version approval, all authors; liter-
ature research, F.S., F.P., G.D., S.
Manoukian, A.F.; clinical studies, R.M.,
G.T., S. Morassut, C.d.G., S. Corcione,
S. Cirillo, V.M., A. Cilotti, C.D.M., A.F.,
L.P., C.Z., A. Contegiacomo, A.O., M.C.,
E.D.C., M.T., P.P., A.D.M.; statistical
analysis, F.S., A.V., M.S., A.F.; and
manuscript editing, F.S., F.P., S. Man-
oukian
BREAST IMAGING:Multicenter Multimodality Surveillance Sardanelli et al
Radiology: Volume 242: Number 3—March 2007 713
References
1. Jemal A, Tiwari RC, Murray T, et al. Cancer
statistics, 2004. CA Cancer J Clin 2004;54:
8–29.
2. Siesling S, van Dijck JA, Visser O, Coebergh
JW;Working Group of the Netherlands Can-
cer Registry. Trends in incidence of and
mortality from cancer in the Netherlands in
the period 1989–1998. Eur J Cancer 2003;
39:2521–2530.
3. Israeli D, Tartter PI, Brower ST, Mizrachy B,
Bratton J. The significance of family history
for patients with carcinoma of the breast.
J Am Coll Surg 1994;179:29–32.
4. Hoskins KF, Stopfer JE, Calzone KA, et al.
Assessment and counseling for women with
a family history of breast cancer: a guide for
clinicians. JAMA 1995;273:577–585.
5. Claus EB, Schildkraut JM, Thompson WD,
Risch NJ. The genetic attributable risk of
breast and ovarian cancer. Cancer 1996;77:
2318–2324.
6. Ford D, Easton DF, Stratton M, et al. Ge-
netic heterogeneity and penetrance analysis
of the BRCA1 and BRCA2 genes in breast
cancer families. Am J Hum Genet 1998;62:
676–689.
7. Podo F, Sardanelli F, Canese R, et al. The
Italian multi-centre project on evaluation of
MRI and other imaging modalities in early
detection of breast cancer in subjects at high
genetic risk. J Exp Clin Cancer Res 2002;
21(suppl 3):115–124.
8. Serova OM, Mazoyer S, Puget N, et al. Mu-
tations in BRCA1 and BRCA2 in breast can-
cer families: are there more breast cancer
susceptibility genes? Am J Hum Genet 1997;
60:486–495.
9. Szabo CI, King MC. Population genetics of
BRCA 1 and BRCA2. Am J Hum Genet 1997;
60:1013–1020.
10. Krainer M, Silva Arrieta S, Fitzgerald MG, et
al. Differential contribution of BRCA1 and
BRCA2 to early-onset breast cancers. N Engl
J Med 1997;336:1416–1421.
11. Pathology of familial breast cancer: differ-
ences between breast cancers in carriers of
BRCA1 or BRCA2 mutations and sporadic
cases. Breast Cancer Linkage Consortium.
Lancet 1997;349:1505–1510.
12. Lakhani SR, Jacquemier J, Sloane JP, et al.
Multifactorial analysis of differences be-
tween sporadic breast cancers and cancers
involving BRCA1 and BRCA2 mutations.
J Natl Cancer Inst 1998;90:1138–1135.
13. Porter DE, Dixon M, Smyth E, Steel CM.
Breast cancer survival in BRCA1 carriers.
Lancet 1993;341:184–185.
14. Verhoog LC, Brekelmans CT, Seynaeve C, et
al. Survival and tumour characteristics of
breast-cancer patients with germline muta-
tions of BRCA1. Lancet 1998;351:316–321.
15. Lehman CD, Schnall MD. Imaging in breast
cancer: magnetic resonance imaging. Breast
Cancer Res 2005;7:215–219.
16. Heywang-Kobrunner SH, Heinig A, Pickuth
D, et al. Interventional MRI of the breast:
lesion localization and biopsy. Eur Radiol
2000;10:36–45.
17. Liberman L, Morris EA, Dershaw DD, et al.
Fast MRI-guided vacuum-assisted breast
biopsy: initial experience. AJR Am J Roent-
genol 2003;181:1283–1293.
18. Kuhl CK, Kreft BP, Bieling HB, et al. Dy-
namic breast MRI in premenopausal healthy
volunteers: normal values of contrast en-
hancement and cycle phase dependency. Ra-
diology 1997;203:137–144.
19. Mu¨ller-Schimpfle M, Ohmeauser K, Stoll P,
Dietz K, Claussen CD. Menstrual cycle and
age: influence on parenchymal contrast me-
dium enhancement in MR imaging of the
breast. Radiology 1997;203:145–149.
20. Liberman L, Morris EA, Benton CL, Abram-
son AF, Dershaw DD. Probably benign le-
sions at breast magnetic resonance imaging:
preliminary experience in high-risk women.
Cancer 2003;98:377–388.
21. Stoutjesdijk MJ, Boetes C, Jager GJ, et al.
Magnetic resonance imaging and mammog-
raphy in women with a hereditary risk of
breast cancer. J Natl Cancer Inst 2001;93:
1095–1102.
22. Morris EA, Liberman L, Ballo DJ. MRI of
occult breast carcinoma in a high-risk popu-
lation. AJR Am J Roentgenol 2003;181:619–
626.
23. Tilanus-Linthorst MM, Obdeijn IM, Bartels
KC, de Koning HJ, Oudkerk M. First experi-
ences in screening women at high risk for
breast cancer with MR imaging. Breast Can-
cer Res Treat 2000;63:53–60.
24. Kuhl CK, Schmutzler RK, Leutner CC, et al.
Breast MR imaging screening in 192 women
proved or suspected to be carriers of a
breast cancer susceptibility gene: prelimi-
nary results. Radiology 2000;215:267–279.
25. Kriege M, Brekelmans CT, Boetes C, et al.
Efficacy of MRI and mammography for
breast cancer screening in women with a
familial or genetic predisposition. N Engl
J Med 2004;351:427–437.
26. Warner E, Plewes DB, Hill KA, et al. Surveil-
lance of BRCA1 and BRCA2 mutation carri-
ers with magnetic resonance imaging, ultra-
sound, mammography, and clinical breast
examination. JAMA 2004;292:1317–1325.
27. Leach MO, Boggis CR, Dixon AK, et al.
Screening with magnetic resonance imaging
and mammography of a UK population at
high familial risk of breast cancer: a prospec-
tive multicentre cohort study (MARIBS).
Lancet 2005;365:1769–1778.
28. Sardanelli F, Podo F. Women with history of
breast cancer excluded from screening
programs: is it the right choice? [letter]. Ra-
diology 2005;234:971.
29. Grompe M. The rapid detection of unknown
mutations in nucleic acids. Nat Genet 1993;
5:111–117.
30. Rosenblum BB, Lee LG, Spurgeon SL, et al.
New dye-labeled terminators for improved
DNA sequencing patterns. Nucleic Acids Res
1997;25:4500–4504.
31. Yager TD, Baron L, Batra R, et al. High
performance DNA sequencing, and the de-
tection of mutations and polymorphisms, on
the Clipper sequencer. Electrophoresis
1999;20:1280–1300.
32. Kourkine IV, Hestekin CN, Barron AE.
Technical challenges in applying capillary
electrophoresis-single strand conformation
polymorphism for genetic analysis. Electro-
phoresis 2002;23:1375–1385.
33. Jones AC, Austin J, Hansen N, et al. Optimal
temperature selection for mutation detec-
tion by denaturing HPLC and comparison to
single-stranded conformation polymorphism
and heteroduplex analysis. Clin Chem 1999;
45:1133–1140.
34. American College of Radiology. Reporting
system. In: Breast imaging reporting and
data system (BI-RADS). 3rd ed. Reston, Va:
American College of Radiology, 1998.
35. Mendelson EB, Berg WA, Merrit CR. Toward
a standardized breast ultrasound lexicon: BI-
RADS—ultrasound. Semin Roentgenol 2001;
36:217–225.
36. Sardanelli F, Iozzelli A, Fausto A. MR imag-
ing of the breast: indications, established
technique and new directions. Eur Radiol
2003;13(suppl 3):N28–N36.
37. Sardanelli F, Fausto A, Iozzelli A, Rescinito
G, Calabrese M. Dynamic breast magnetic
resonance imaging: effect of changing the
region of interest on early enhancement us-
ing 2D and 3D techniques. J Comput Assist
Tomogr 2004;28:642–646.
38. Fischer U, Kopka L, Grabbe E. Breast
carcinoma: effect of preoperative contrast-
enhanced MR imaging on the therapeutic ap-
proach. Radiology 1999;213:881–888.
39. Baum F, Fischer U, Vosshenrich R, Grabbe
E. Classification of hypervascularized lesions
in CE MR imaging of the breast. Eur Radiol
2002;12:1087–1092.
BREAST IMAGING:Multicenter Multimodality Surveillance Sardanelli et al
714 Radiology: Volume 242: Number 3—March 2007
40. Liberman L, Menell JH. Breast imaging re-
porting and data System (BI-RADS). Radiol
Clin North Am 2002;40:409–430.
41. Cancer statistics in developing countries: re-
port on a WHO meeting, Nagoya, Japan,
18–22 August, 1981. World Health Stat Q
1983;36:213–217.
42. Glantz SA. Primer of biostatistics. 4th ed.
New York, NY: McGraw-Hill, 1997; 140–150.
43. Caines JS, Schaller GH, Iles SE, et al. Ten
years of breast screening in the Nova Scotia
Breast Screening Program, 1991–2001. Can
Assoc Radiol J 2005;56:82–93.
44. Brekelmans CT, Seynaeve C, Bartels CC, et
al. Effectiveness of breast cancer surveil-
lance in BRCA1/2 gene mutation carriers
and women with high familial risk. J Clin
Oncol 2001;19:924–930.
45. Jassem J, Buchanan M, Janicke F, et al. The
Hamburg statement: the partnership driving
the European agenda on breast cancer. Eur J
Cancer 2004;40:1810–1811.
46. Robson M, Gilewki T, Haas B, et al. BRCA-
associated breast cancer in young women.
J Clin Oncol 1998;16:1642–1649.
47. Tilanus-Linthorst MM, Kriege M, Boetes C,
et al. Hereditary breast cancer growth rates
and its impact on screening policy. Eur J
Cancer 2005;41:1610–1617.
48. Chart PL, Franssen E. Management of
women at increased risk for breast cancer:
preliminary results from a new program.
CMAJ 1997;157:1235–1242.
49. Lalloo F, Boggis CR, Evans DG, Shenton A,
Threlfall AG, Howell A. Screening by mam-
mography, women with a family history of
breast cancer. Eur J Cancer 1998;34:937–
940.
50. Morris EA. Breast MRI for cancer screen-
ing in high-risk patients. Appl Radiol 2005;
May(suppl):4-9.
BREAST IMAGING:Multicenter Multimodality Surveillance Sardanelli et al
Radiology: Volume 242: Number 3—March 2007 715
